MuSK抗体阳性的重症肌无力诊断及治疗最新进展

Abstract
Figure/Table
References
Related Citation (15)

[1]	张志豪,邬冬强,肖怀清,等.单孔胸腔镜下手术治疗重症肌无力5例[J].武警医学, 2019,30(6):531-533.
[2]	母艳蕾,张华,陈海波,等.不同抗体分型的重症肌无力特点分析[J].中国神经免疫学和神经病学杂志,2019,26(2):103-109.
[3]	Lazaridis K, Tzartos S J. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics[J]. Front Immunol, 2020,11:212.
[4]	Rivner M H, Pasnoor M, Dimachkie M M, et al. Muscle-Specific tyrosine kinase and myasthenia gravis owing to other antibodies[J]. Neurol Clin, 2018,36(2):293-310.
[5]	Panos S, Aditya K, Heiden J A, et al. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis[J]. Ann NY Acad of Sci, 2018,1412(1):154-165.
[6]	Han J, Zhang J, Li M, et al. A novel MuSK cell-based myasthenia gravis diagnostic assay[J]. J Neuroimmunol, 2019,337:577076.
[7]	Yi J S, Guptill J T, Stathopoulos P, et al. B cells in the pathophysiology of myasthenia gravis[J]. Muscle Nerve, 2018,57(2):172-184.
[8]	Hurst R L, Gooch C L. Muscle-Specific receptor tyrosine kinase (MuSK) myasthenia gravis[J]. Curr Neurol Neurosci Rep, 2016,16(7):61.
[9]	鲁亚茹,欧昶毅,邱力,等.我国华南地区MuSK抗体阳性重症肌无力患者的临床特点[J].中国神经免疫学和神经病学杂志,2020,27(1):15-19.
[10]	Evoli A, Alboini P E, Damato V, et al. Myasthenia gravis with antibodies to MuSK: an update[J]. Ann N Y Acad Sci, 2018,1412(1):82-89.
[11]	Vincent A, Huda S, Cao M, et al. Serological and experimental studies in different forms of myasthenia gravis[J]. Ann N Y Acad Sci, 2018,1413(1):143-153.
[12]	沈发秀,李尊波,雷霖,等.MuSK抗体阳性重症肌无力10例临床分析[J].中国神经精神疾病杂志, 2020,46(1):24-28.
[13]	刘怡琳,郑艺明,罗晶晶,等.重症肌无力抗体测定数值分布特征与相关分析[J].中华医学杂志, 2019,99(41):3221-3226.
[14]	Park K H, Waters P, Woodhall M, et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies in south korea: autoantibody profiles and clinical features[J]. PLoS One, 2018,13(3): e0193723.
[15]	Martignago S, Fanin M, Albertini E, et al. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR[J]. Neuropathol Appl Neurobiol, 2009,35(1):103-110.
[16]	Shin H Y, Park H J, Lee H E, et al. Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis: Evidence for Cholinergic Neuromuscular Hyperactivity[J]. J Clin Neurol, 2014,10(2):119-124.
[17]	Jian F, Wang H B, Chen N, et al. Observation of clinical and electrophysiological features in patients with distal myasthenia gravis[J]. Zhonghua Yi Xue Za Zhi, 2017,97(37):2894-2897.
[18]	母艳蕾,张华,国红,等. AChR及MuSK双抗体阳性重症肌无力三例并文献复习[J].中国神经免疫学和神经病学杂志,2018,25(2):80-86.
[19]	曹姗,郝洪军,刘永刚,等.抗MuSK抗体阳性的重症肌无力合并Graves病1例[J].中国现代神经疾病杂志,2019,19(2):137-140.
[20]	刘卫彬.重症肌无力管理国际共识(2016)的创新与中国实践[J].中华医学杂志,2017,97(37):2881-2883.
[21]	孙静洁, 王琪. 小剂量激素联合免疫抑制药在Ⅰ,Ⅱ型重症肌无力患者中的疗效观察及对细胞免疫水平的影响研究[J].中国免疫学杂志,2019, 35(21):2628-2632.
[22]	李芳芳.单链抗体融合人血清白蛋白的制备及对重症肌无力患者血清的抑制作用[D].吉林:延边大学,2014.
[23]	柏萃.重症肌无力治疗方法疗效的比较[D].重庆:重庆医科大学,2010.
[24]	Singh N, Goyal V. Rituximab as induction therapy in refractory myasthenia gravis: 18?month follow-up study[J]. J Neurol, 2019,266(7):1596-1600.
[25]	Einarsson J T, Evert M, Geborek P, et al. Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies[J]. Clin Rheumatol, 2017,36(12):2743-2750.
[26]	Grace R F, Shimano K A, Bhat R, et al. Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes[J]. Am J Hematol, 2019,94(7):741-750.
[27]	Dalakas M C. Immunotherapy in myasthenia gravis in the era of biologics[J]. Nat Rev Neurol, 2019,15(2):113-124.
[28]	Keung B, Robeson K R, DiCapua D B, et al. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients[J]. J Neurol Neurosurg Psychiatry, 2013,84(12):1407-1409.
[29]	Topakian R, Zimprich F, Iglseder S, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria[J]. J Neurol, 2019,266(3):699-706.
[30]	Clifford K M, Hobson-Webb L D, Benatar M, et al. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis[J]. Muscle Nerve, 2019,59(4):404-410.